Fu-An Kang

WuXi XDC is a leading CRDMO focused on the global ADC and broader bioconjugate market and is dedicated to providing integrated services from concept development to commercialization. All services are provided from proximately located, state-of-the-art laboratories and manufacturing facilities, providing high efficiency and significant reduction of development timeline and costs. Our community of over 1000 skilled employees work across a global network to provide an open-access platform with the most comprehensive capabilities and technologies. WuXi XDC enables its biopharmaceutical partners to innovate, accelerate, and transform the development of the bioconjugate industry, to the benefit of patients worldwide.

AcceleDev is a chemistry CDMO specializing in small molecule custom synthesis including linker materials for bioconjugates, with R&D and GMP manufacturing facilities in the US and China. We support pharma partners from preclinical to commercial stages with process chemistry, analytical development, scale-up, and supply chain services. Known for solving complex challenges with speed and innovation, our experienced team delivers scalable solutions and full CMC support. With over 20 years of success across thousands of projects, AcceleDev is trusted for its quality, agility, and customer-first approach.

miRecule™ is an early-stage biotechnology company developing RNA-based therapeutics. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality. miRecule is currently applying the DREAmiR™ platform to develop first-in-class therapies, with lead programs in Head & Neck Cancer and Muscular Dystrophy. The 2nd Next Generation Conjugate Summit, February 21-23, 2023, Boston. Development of Antibody Oligonucleotide Conjugates as Tissue-Targeted RNA Therapies. The Inaugural Novel Format Conjugate Summit, April 25-27, 2022, Boston. Harnessing Novel Antibody Oligonucleotide Conjugates as Targeted miRNA Therapy Inhibiting RTK Signaling & Drug Resistance in Head & Neck Cancer. World Intellectual Property Organization, Compositions for Delivery of Polynucleotides, WO2023122347A3, 2023-09-07. The 13th Annual World ADC Summit, San Diego, 2022. Development of MC-DX4 as an Antibody ASO Conjugate Therapeutic for Facioscapulohumeral Muscular Dystrophy (FSHD) The 13th Annual World ADC Summit, San Diego, 2022. Development of the BioCoat-Formulated Antibody-Oligonucleotide Conjugates for the Treatment of Head and Neck Cancer. The 17th Annual Meeting of the Oligonucleotide Therapeutics Society, 2021. The DREAmiR Discovery Platform For RNA Therapeutics Development: MC-30 As The Best-In-Class Therapy For HNSCC. The 12th Annual World ADC Summit, San Diego, 2021. Discovery and Development of Antibody Oligonucleotide Conjugates To Treat Head and Neck Cancer.

Abzena is a life sciences group that provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry. Journal of Antibody-Drug Conjugates (ADC Review), April 8, 2020. DOI: 10.14229/jadc.2020.04.08.001. Addressing the Challenges of Bioconjugate Medicines. United States, US11014940 B1 2021-05-25. Thiazolidinone and oxazolidinone compounds and their preparation, pharmaceutical compositions and use in the treatment of multiple sclerosis and psoriasis. World Intellectual Property Organization, WO2018183917 A1 2018-10-04. Process for and intermediates in the kilogram-scale preparation of the antibacterial agent TXA709 and its mesylate salt. World Intellectual Property Organization, WO2018051109 A1 2018-03-22. Preparation of novel maytansinoid compounds and their conjugates as cytotoxic agents. Progress in Heterocyclic Chemistry 2015, 27, 29-59. Recent progress of phosphonium coupling in heterocyclic and medicinal chemistry. Science of Synthesis 2015, 2, 173-239. Quinazolines.

Wilmington PharmaTech Company LLC is a leading global service company specializing in the research and development of today’s medicines, including custom synthesis, process chemistry, medicinal chemistry, cGMP API manufacturing, polymorph screening and salt selection, and analytical services. Organic Process Research & Development 2014, 18, 1630-1640. Lab Scale Preparation of a Novel Cyclopenta[b]furan Chemokine Receptor Antagonist. Organic Process Research & Development 2014, 18, 1622-1629. Lab Scale Preparation of a Novel Carbocyclic Chemokine Receptor Antagonist. Tetrahedron: Asymmetry 2013, 24, 651–656. Chiral aminocyclopentene-based cycloaddition strategies to bicyclic [3.3.0] rings.

Santai Labs is an innovative R&D company that provides high quality pre-clinical services to customers and partners to speed up their drug discovery and development efforts. Bioorganic & Medicinal Chemistry Letters 2013, 23, 351-354. Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists, Tetrahedron Letters 2012, 53, 1928-1932. A balanced linear equation of the extended Woodward UV rules for all types of alpha,beta-unsaturated ketones. Bioorganic & Medicinal Chemistry Letters 2011, 21 (24), 7496-7501. The discovery of novel cyclohexylamide CCR2 antagonists, Tetrahedron Letters 2011, 52, 6679-6681. A linear mathematical relationship hidden in the Woodward UV rules for alpha,beta-unsaturated ketones. Journal of Chemical Education 2011, 88 (4), 420. A simple computer-aided three-dimensional molecular modeling for the octant rule.

Johnson & Johnson embraces research and science, bringing innovative ideas, products and services to advance the health and well-being of people, and touching the lives of over a billion people every day throughout the world. Tetrahedron Letters 2011, 52, 4204. A diversity-oriented-synthesis protocol for scaffold discovery based on a general synthetic route to spirocycles. Chemical Communications 2010, 46 (8), 1347-1349. Direct dehydrative cross-coupling of tautomerizable heterocycles with alkynes via Pd/Cu catalyzed phosphonium coupling. European Journal of Organic Chemistry 2009, (4), 461-479. Phosphonium coupling in the direct bond formations of tautomerizable heterocycles via C-OH bond activation. Journal of the American Chemical Society 2008, 130 (34), 11300-11302. Pd-Catalyzed direct arylation of tautomerizable heterocycles with aryl boronic acids via C-OH bond activation using phosphonium salts. Bioorganic & Medicinal Chemistry Letters 2008, 18 (13), 3687-3690. Insight from molecular modeling into different conformation and SAR of natural steroids and unnatural 7-oxa-steroids. Bioorganic & Medicinal Chemistry Letters 2007, 17, 2531-2534. Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2007, 17, 907-910. Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists. Tetrahedron Letters 2007, 48, 193-197. Enantioselective synthesis of (8S,13S,14R)-7-oxa-estra-4,9-diene-3,17-dione. Tetrahedron Letters 2006, 47, 9021-9024. Stereoselective synthesis of (8R,13S,14S)-7-oxa-estra-4,9-diene-3,17-dione. Journal of Organic Chemistry 2005, 70 (5), 1957-1960. Efficient conversion of Biginelli 3,4-dihydropyrimidin-2(1H)-one to pyrimidines via PyBroP-mediated coupling.

Pure and Applied Chemistry 2003, 75, 1-17. Synthetic studies on the marine natural products Halichondrins. Organic Letters 2002, 4 (25), 4435-4438. Asymmetric Ni(II)/Cr(II)-mediated coupling reaction: catalytic process. Organic Letters 2002, 4 (25), 4431-4434. Asymmetric Ni(II)/Cr(II)-mediated coupling reaction: stoichiometric process.